News stories about Adamas Pharmaceuticals (NASDAQ:ADMS) have been trending somewhat positive on Thursday, according to Accern. Accern identifies positive and negative news coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Adamas Pharmaceuticals earned a news sentiment score of 0.21 on Accern’s scale. Accern also gave headlines about the specialty pharmaceutical company an impact score of 45.535356518963 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
These are some of the news articles that may have impacted Accern’s scoring:
NASDAQ:ADMS traded up $1.74 during trading hours on Thursday, hitting $27.59. 742,838 shares of the company were exchanged, compared to its average volume of 978,392. The firm has a market cap of $670.45, a P/E ratio of -6.51 and a beta of 1.59. The company has a quick ratio of 10.69, a current ratio of 10.79 and a debt-to-equity ratio of 1.55. Adamas Pharmaceuticals has a one year low of $13.50 and a one year high of $44.00.
Adamas Pharmaceuticals (NASDAQ:ADMS) last posted its quarterly earnings data on Thursday, February 22nd. The specialty pharmaceutical company reported ($1.27) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.18) by ($0.09). The firm had revenue of $0.57 million during the quarter, compared to analysts’ expectations of $0.84 million. During the same period in the previous year, the business posted ($0.68) earnings per share. The company’s quarterly revenue was up 1435.1% on a year-over-year basis. equities research analysts expect that Adamas Pharmaceuticals will post -5.87 EPS for the current year.
Several research firms have recently commented on ADMS. Leerink Swann began coverage on Adamas Pharmaceuticals in a research report on Wednesday, April 4th. They issued an “outperform” rating and a $31.00 target price on the stock. ValuEngine raised Adamas Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Monday, April 2nd. BidaskClub downgraded Adamas Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, March 27th. Bank of America began coverage on Adamas Pharmaceuticals in a research report on Tuesday, March 27th. They set a “buy” rating and a $39.00 price target on the stock. Finally, Needham & Company LLC set a $40.00 price target on Adamas Pharmaceuticals and gave the stock a “buy” rating in a research report on Sunday, February 25th. Two investment analysts have rated the stock with a sell rating and twelve have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $42.89.
In other news, insider Rajiv Patni sold 1,252 shares of the firm’s stock in a transaction dated Wednesday, March 21st. The stock was sold at an average price of $25.94, for a total value of $32,476.88. Following the completion of the sale, the insider now directly owns 21,515 shares in the company, valued at approximately $558,099.10. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Gregory T. Went sold 4,541 shares of Adamas Pharmaceuticals stock in a transaction dated Wednesday, March 21st. The shares were sold at an average price of $25.75, for a total value of $116,930.75. Following the transaction, the chief executive officer now owns 182,610 shares of the company’s stock, valued at approximately $4,702,207.50. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 6,360 shares of company stock valued at $164,138. 29.00% of the stock is currently owned by company insiders.
ILLEGAL ACTIVITY WARNING: “Somewhat Favorable Press Coverage Somewhat Unlikely to Affect Adamas Pharmaceuticals (ADMS) Share Price” was published by Macon Daily and is owned by of Macon Daily. If you are accessing this news story on another website, it was copied illegally and republished in violation of U.S. & international copyright legislation. The original version of this news story can be accessed at https://macondaily.com/2018/04/19/adamas-pharmaceuticals-adms-receives-news-impact-rating-of-0-21-updated.html.
About Adamas Pharmaceuticals
Adamas Pharmaceuticals, Inc discovers, develops, and sells therapies for chronic neurologic disorders. The company's approved/commercial product is GOCOVRI, an amantadine therapy for the treatment of levodopa-induced dyskinesia in patients with Parkinson's disease. Its partnered approved/commercial products include Namzaric (memantine hydrochloride extended-release and donepezil hydrochloride) capsules; and Namenda XR (memantine hydrochloride) extended release capsules for the treatment of moderate to severe Alzheimer's disease.
Receive News & Ratings for Adamas Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.